We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
28
Sep 2026
Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and sexual side effects than surgery in the first randomized trial to directly compare the treatments for localized prostate cancer.
28
Sep 2026
HR+/HER2− breast cancer constitutes approximately 65–75% of all breast cancer cases worldwide. Although CDK4/6 inhibitors have substantially extended progression-free survival (PFS), up to 60% of patients derive no clinical benefit from these agents, underscoring the urgent need for more effective therapeutic strategies.
28
Sep 2026
Starting in July 2029, public schools are required to start phasing out ultra-processed foods under a new California law that prohibits schools from serving foods high in sugar, fat, salt and certain artificial food additives.
28
Sep 2026
Patients with small cell lung cancer (SCLC) that had spread to the brain lived a median of 17 months after focused stereotactic radiosurgery, compared with nine months after an advanced form of whole brain radiation therapy, an unexpected secondary finding from the first randomized phase 3 trial to compare the treatment approaches in this population.